Skip to main content
OpenTrials
Completed

NCT Number: NCT04833439

The Effect of a Fasting MimickINg Diet on the Immune System

Fasting or a Fasting Mimicking diet (FMD) can lower blood concentration of glucose and IGF1. Since cancer cells rely mostly on a glucose-based metabolism, FMD renders cancer cells more vulnerable to chemotherapy, thereby enhancing therapeutic efficacy. This process is known as differential stress sensitization (DSS). Another response to nutritional stress by fasting is known as differential stress resistance (DSR). DSR is a state in which healthy cells rather focus resources on protection and internal repair, which can result in reduced chemotherapeutic toxicity. Recent preclinical studies found that fasting or FMD not only aids healthy cell protection, but also has the potential to benefit effector T-cells and could thereby improve antitumor immunity. However in most oncotherapeutic clinical trials investigating the addition of a fasting regimen, other factors such as chemotherapy, surgery and additional medication affect the immune system as well. That is why this explorative study, conducted in healthy subjects, might be more suitable to investigate the immunological alterations upon FMD more specifically. This exploratory study aims to identify immunological alterations by using extensive immunoprofiling before and after three days of FMD in healthy subjects, as well as investigate possible side effects of FMD.

Completed

Looking for future studies?

Notify Me

Key information

Age range

18 year and older

Sex eligibility

All sexes

Study type

Interventional

Phase

Not applicable

Primary location

Leiden University Medical Center

Leiden, South Holland, 2333 ZA, Netherlands

Who can participate

Healthy volunteers accepted: Yes

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • ≥18 years old
  • BMI ≥18.5 and ≤25kg/m2

Exclusion criteria

  • Chronic disease or active infection
  • Medication use other than contraceptive, during the last 12 weeks prior to inclusion.
  • A history of allergy
  • Blood or plasma donation in the last 12 weeks prior to inclusion.
  • Participation in other medical research in the last 12 weeks prior to inclusion.

Treatment and study plan

Fasting Mimicking diet

Other

Low-caloric, low-protein, plant-based diet regiment for 3 days

Other names: Xentigen

Primary outcomes

  1. Change in gene expression signature in peripheral blood mononuclear cells (PBMCs) after overnight fast and after completion of 2 cycles of fasting mimicking diet compared to baseline.

    Time frame: 4 weeks

    PBMCs are retrieved from whole blood samples. Gene expression signature is retrieved from PBMCs using RNA-Nanostring technique with the Pancancer IO 360 panel. The Nanostring will report RNA counts for a panel of 770 genes, including 40 housekeeping genes. The data will be normalized on the 40 housekeeping genes for internal control using Nanostring nSolver software. The fold change from baseline to overnight fast and after completion of second fasting mimicking diet will provide insight in affected pathways as well as metabolic and immune signatures.

Secondary outcomes

  1. Change in immune cell properties from PBMCs after overnight fast and after 2 cycles of fasting mimicking diet compared to baseline.

    Time frame: 6 months

    PBMCs retrieved from whole blood samples will be analysed with a 40-plex Aurora flowcytometry panel with markers for T cells and myeloid cells. The flow cytometry will generate frequencies of the different immune cell markers,. A comparison of the frequency data between blood samples will determine change in immune cell properties.

    This analysis will be used to confirm and complement gene expression signature findings on a protein level.

  2. Change in plasma concentration of IGF1, glucose and ketone bodies (Beta-hydroxybutyric acid) after overnight fast and after completion of 2 cycles of fasting mimicking diet compared to baseline.

    Time frame: 4 weeks

    Measured in blood plasma taken at 3 time points.

  3. Percentage of participants reporting adverse events as assessed by CTCAE v5.0 during fasting mimicking diet

    Time frame: 8 weeks

    Descriptive analysis of adverse events by type and grade according to NCI CTCAE v5.0 experienced by participants during fasting mimicking diet assessed after second cycle on day 22.

Sponsors and collaborators

Lead sponsor

Leiden University Medical Center

Other

Registry information

Official study title

The Effect of a Fasting MimickINg Diet on the Immune System: an Exploratory Study

Acronym: FIND

Important dates

Study start
2021
Primary completion
2022
Study completion
2022
First posted
Apr 6, 2021
Registry last updated
Jul 27, 2022

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.